Please try another search
For the nine months ended 30 September 2017, PharMerica Corporation revenues increased 13% to $1.75B. Net income decreased 18% to $11.4M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was offset by Selling, general and administrative expe increase of 13% to $187.5M (expense), Amortization expense increase of 17% to $29M (expense), Interest expense.
Period Ending: | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Revenue | 595.1 | 592 | 566.8 | 534.4 |
Gross Profit | 89.3 | 89.6 | 87.9 | 83.7 |
Operating Income | 10.2 | 11.6 | 9.2 | 11 |
Net Income | 3.2 | 4.7 | 3.5 | 7.7 |
Period Ending: | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Total Assets | 1268.4 | 1236.7 | 1252.3 | 1273 |
Total Liabilities | 706.8 | 679.9 | 701.9 | 728.8 |
Total Equity | 561.6 | 556.8 | 550.4 | 544.2 |
Period Ending: | Sep 30, 2017 | Jun 30, 2017 | Mar 31, 2017 | Dec 31, 2016 |
---|---|---|---|---|
Period Length: | 9 Months | 6 Months | 3 Months | 12 Months |
Cash From Operating Activities | 132.7 | 114.7 | 72.2 | 30.8 |
Cash From Investing Activities | -117.4 | -66.6 | -56.1 | -91.7 |
Cash From Financing Activities | -12.9 | -40 | -6.1 | 43.2 |
Net Change in Cash | 2.4 | 8.1 | 10 | -17.7 |
Unlock access to over 1000 metrics with InvestingPro
View advanced insights on financial statements, including growth rates and metrics that provide an in-depth view of the company's historical and forecasted financial performance.
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review